CN118420777A - 一种抗dll3嵌合抗原受体及其用途 - Google Patents
一种抗dll3嵌合抗原受体及其用途 Download PDFInfo
- Publication number
- CN118420777A CN118420777A CN202410399472.2A CN202410399472A CN118420777A CN 118420777 A CN118420777 A CN 118420777A CN 202410399472 A CN202410399472 A CN 202410399472A CN 118420777 A CN118420777 A CN 118420777A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- car
- dll3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4225—Growth factors
- A61K40/4229—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019096360 | 2019-07-17 | ||
| CNPCT/CN2019/096360 | 2019-07-17 | ||
| CN2020090587 | 2020-05-15 | ||
| CNPCT/CN2020/090587 | 2020-05-15 | ||
| PCT/CN2020/102717 WO2021008610A1 (en) | 2019-07-17 | 2020-07-17 | Anti-dll3 chimeric antigen receptors and uses thereof |
| CN202080047990.8A CN114072427B (zh) | 2019-07-17 | 2020-07-17 | 抗dll3嵌合抗原受体及其用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080047990.8A Division CN114072427B (zh) | 2019-07-17 | 2020-07-17 | 抗dll3嵌合抗原受体及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118420777A true CN118420777A (zh) | 2024-08-02 |
Family
ID=74210175
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410399472.2A Pending CN118420777A (zh) | 2019-07-17 | 2020-07-17 | 一种抗dll3嵌合抗原受体及其用途 |
| CN202080047990.8A Active CN114072427B (zh) | 2019-07-17 | 2020-07-17 | 抗dll3嵌合抗原受体及其用途 |
| CN202311129421.XA Pending CN117106099A (zh) | 2019-07-17 | 2020-07-17 | 一种抗dll3嵌合抗原受体及其用途 |
| CN202410399887.XA Pending CN118496374A (zh) | 2019-07-17 | 2020-07-17 | 一种抗dll3嵌合抗原受体及其用途 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080047990.8A Active CN114072427B (zh) | 2019-07-17 | 2020-07-17 | 抗dll3嵌合抗原受体及其用途 |
| CN202311129421.XA Pending CN117106099A (zh) | 2019-07-17 | 2020-07-17 | 一种抗dll3嵌合抗原受体及其用途 |
| CN202410399887.XA Pending CN118496374A (zh) | 2019-07-17 | 2020-07-17 | 一种抗dll3嵌合抗原受体及其用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12421292B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4527466A3 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7748933B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220035367A (cg-RX-API-DMAC7.html) |
| CN (4) | CN118420777A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020314509A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3146019A1 (cg-RX-API-DMAC7.html) |
| TW (2) | TW202535924A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021008610A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021180215A1 (en) | 2020-03-12 | 2021-09-16 | Nanjing Legend Biotech Co., Ltd. | Glypican-2-binding moieties, chimeric antigen receptors and uses thereof |
| US20240150456A1 (en) * | 2021-04-02 | 2024-05-09 | Nanjing Legend Biotech Co., Ltd. | Engineered immune cells and uses thereof |
| CA3230627A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting dll3 and uses thereof |
| EP4499680A1 (en) * | 2022-03-29 | 2025-02-05 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
| WO2024006281A2 (en) * | 2022-06-28 | 2024-01-04 | Carisma Therapeutics Inc. | Switch receptors and modified immune cells |
| JP2025525496A (ja) * | 2022-07-08 | 2025-08-05 | イマジナブ・インコーポレーテッド | Dll3抗原結合構築物 |
| US20260061051A1 (en) * | 2022-08-26 | 2026-03-05 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
| CN115820698B (zh) * | 2022-11-22 | 2025-01-21 | 浙江康佰裕生物科技有限公司 | 含有嵌合抗原受体和嵌合转换开关受体编码基因的融合基因及其应用 |
| CN116004547B (zh) * | 2023-03-06 | 2025-04-25 | 浙江康佰裕生物科技有限公司 | 一种辐照car-t细胞及其制备方法与应用 |
| CN121152872A (zh) * | 2023-05-10 | 2025-12-16 | 南京传奇生物科技有限公司 | 嵌合抗原受体及其使用方法 |
| KR20260079181A (ko) * | 2023-09-26 | 2026-06-01 | 레전드 바이오테크 유에스에이, 인크. | Dll3 결합 모이어티 및 이의 용도 |
| CN122094981A (zh) | 2023-10-16 | 2026-05-26 | 上海先博生物科技有限公司 | 一种靶向δ样配体3的CAR及应用 |
| WO2025201493A1 (zh) * | 2024-03-29 | 2025-10-02 | 诺纳生物(苏州)有限公司 | Dll3结合分子及其用途 |
| WO2025212519A1 (en) * | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
| WO2025240849A1 (en) * | 2024-05-16 | 2025-11-20 | The Brigham And Women's Hospital, Inc. | Trem2 chimeric antigen receptors and uses thereof |
| WO2026008059A1 (en) * | 2024-07-04 | 2026-01-08 | Nanjing Legend Biotech Co., Ltd. | Anti-dll3 constructs and uses thereof |
| WO2026052061A1 (en) * | 2024-09-05 | 2026-03-12 | Nanjing Legend Biotech Co., Ltd. | Adoptive cell compositions |
| WO2026051938A1 (en) * | 2024-09-05 | 2026-03-12 | Therorna Shanghai Co., Ltd. | Circular rna encoding chimeric antigen receptors targeting dll3 and the use thereof |
| CN119708238B (zh) * | 2025-02-27 | 2025-07-04 | 昕传生物科技(北京)有限公司 | 靶向dll3的抗体、嵌合抗原受体及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| MA41613A (fr) | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
| CN105153315B (zh) * | 2015-10-09 | 2019-04-02 | 重庆精准生物技术有限公司 | 免疫抑制受体联合肿瘤抗原嵌合受体及其应用 |
| CA3034691A1 (en) | 2016-08-30 | 2018-03-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| CN108276493B (zh) * | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| JP2020517263A (ja) | 2017-04-19 | 2020-06-18 | ユニバーシティ オブ サザン カリフォルニア | がんを治療するための組成物及び方法 |
| BR112020005938A2 (pt) | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
| US20220025037A1 (en) | 2018-04-03 | 2022-01-27 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting dll3, and use thereof |
| CR20200539A (es) | 2018-04-10 | 2021-07-01 | Kite Pharma Inc | Receptores quiméricos de dll3 y métodos para su uso |
-
2020
- 2020-07-17 EP EP25154055.5A patent/EP4527466A3/en active Pending
- 2020-07-17 TW TW114114222A patent/TW202535924A/zh unknown
- 2020-07-17 AU AU2020314509A patent/AU2020314509A1/en active Pending
- 2020-07-17 TW TW109124309A patent/TWI883026B/zh active
- 2020-07-17 KR KR1020227000346A patent/KR20220035367A/ko active Pending
- 2020-07-17 CA CA3146019A patent/CA3146019A1/en active Pending
- 2020-07-17 CN CN202410399472.2A patent/CN118420777A/zh active Pending
- 2020-07-17 CN CN202080047990.8A patent/CN114072427B/zh active Active
- 2020-07-17 US US17/618,642 patent/US12421292B2/en active Active
- 2020-07-17 EP EP20840073.9A patent/EP3999550A4/en active Pending
- 2020-07-17 CN CN202311129421.XA patent/CN117106099A/zh active Pending
- 2020-07-17 JP JP2022502899A patent/JP7748933B2/ja active Active
- 2020-07-17 WO PCT/CN2020/102717 patent/WO2021008610A1/en not_active Ceased
- 2020-07-17 CN CN202410399887.XA patent/CN118496374A/zh active Pending
-
2025
- 2025-01-31 JP JP2025015341A patent/JP7894963B2/ja active Active
- 2025-08-22 US US19/308,077 patent/US20260078166A1/en active Pending
- 2025-09-22 JP JP2025156914A patent/JP2026001061A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025069305A (ja) | 2025-04-30 |
| CN114072427A (zh) | 2022-02-18 |
| JP2026001061A (ja) | 2026-01-06 |
| EP4527466A3 (en) | 2025-06-18 |
| AU2020314509A1 (en) | 2022-01-06 |
| US20220249563A1 (en) | 2022-08-11 |
| TW202116812A (zh) | 2021-05-01 |
| TWI883026B (zh) | 2025-05-11 |
| US12421292B2 (en) | 2025-09-23 |
| JP7748933B2 (ja) | 2025-10-03 |
| CA3146019A1 (en) | 2021-01-21 |
| CN118496374A (zh) | 2024-08-16 |
| JP7894963B2 (ja) | 2026-07-24 |
| TW202535924A (zh) | 2025-09-16 |
| US20260078166A1 (en) | 2026-03-19 |
| CN114072427B (zh) | 2024-04-26 |
| CN117106099A (zh) | 2023-11-24 |
| EP3999550A1 (en) | 2022-05-25 |
| JP2022542543A (ja) | 2022-10-05 |
| EP4527466A2 (en) | 2025-03-26 |
| EP3999550A4 (en) | 2023-09-06 |
| KR20220035367A (ko) | 2022-03-22 |
| WO2021008610A1 (en) | 2021-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114072427B (zh) | 抗dll3嵌合抗原受体及其用途 | |
| JP6722189B2 (ja) | 単量体Fcドメイン | |
| AU2020287373A1 (en) | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function | |
| CN112639102A (zh) | 抗间皮素嵌合抗原受体(car)构建体及其用途 | |
| CN113195542A (zh) | Cd30-结合部分、嵌合抗原受体及其用途 | |
| JP2018522564A (ja) | 抗グリピカン3抗体およびその使用 | |
| JP2023511482A (ja) | Cd276抗原の抗体ターゲティング、および他のモジュレーター、ならびにその使用 | |
| CN111727057A (zh) | 与lag3和pd1结合的治疗分子 | |
| CN113891718A (zh) | 人工免疫监视嵌合抗原受体(ai-car)及其表达细胞 | |
| WO2015172341A1 (zh) | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 | |
| US20230265185A1 (en) | Anti-cd22 single domain antibodies and therapeutic constructs | |
| HK40110781A (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| HK40110214A (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| HK40098926A (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| HK40065826A (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| HK40065826B (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| WO2025201240A1 (en) | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof | |
| KR20260016889A (ko) | B7-h3을 표적하는 항체, 및 이를 포함하는 키메라 항원 수용체 | |
| CN120137042A (zh) | 一种抗st2单克隆抗体与应用 | |
| WO2025133609A1 (en) | Polypeptide binding glypican-3 | |
| WO2023031300A1 (en) | Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars | |
| CN120775047A (zh) | 靶向Claudin18.2的抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40110781 Country of ref document: HK |